Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) will see its price axed by 23.8% in April as it faces a series of price reduction rules including a new post-launch foreign price adjustment and a cut under an ongoing pilot program for…
To read the full story
Related Article
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
- New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs
March 6, 2018
- Rituxan Biosimilar Price Down 9.5% as Originator Hit by Re-Pricing
March 6, 2018
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- One-Time Blockbusters to Be Re-Priced at 2.5-Times Gx Price Average; Mevalotin, Takepron among the List
March 5, 2018
- Repatha Gets Price Raise as It Wins Post-Launch Premium for CV Risk Reduction
March 5, 2018
- 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
- MHLW Unveils New List Prices, Post-Launch Foreign Price Adjustment Applied Only to Opdivo
March 5, 2018
- Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing
January 18, 2018
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…